Other substances

Vortioxetine

A serotogenic antidepressant.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

General information

Vortioxetine is an atypical antipsychotic and antidepressant. It is used for the treatment of major depressive disorder. Vortioxetine acts through serotonin neurotransmitter system modulation (DrugBank).

Vortioxetine on PubChem
Vortioxetine on Wikipedia

Marketed as

BRINTELLIX; TRINTELLIX

 

Structure image - Vortioxetine

CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C

Supporting references

Link Tested on Impact factor Notes Publication date
Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
Small molecule In vitro Screening 		BHK21-hACE2 cells; SARS-CoV-2 Spike Δ18-pseudotyped virus; SARS-CoV-2 strain BetaCoV/Shenzhen/SZTH-003/2020 4.23

The drug inhibited SARS-CoV-2 pseudovirus and live virus in vitro with IC50s of 7.16 μM (3 μM and 6.77 μM in different experiments) and 8.03 μM, respectively. When combined with clomiphene (citrate) and asenapine (hydrochloride), the observed IC50s for pre-treatment and co-treatment were 0.34 μM and 1.93 μM with SIs of ca. 43 and 8.3, respectively.

 Feb/05/2021
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Small molecule In vitro Screening 		Vero cells 5.09

Inhibits SARS-CoV-2 in Vero cells with a high selectivity index.

 Nov/25/2020

AI-suggested references

Link Publication date
Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19-related trauma.
Oct/30/2020
Panic Disorder Induced by the Coronavirus Disease Pandemic in a Patient with Organic Mood Disorder Successfully Treated with Vortioxetine
Nov/02/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05047952 Vortioxetine for Post-COVID-19 Condition Recruiting Phase 2 Sep/16/2021 Sep/01/2022
  • Alternative id - BCDF002
  • Interventions - Drug: Vortioxetine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Brain and Cognition Discovery Foundation (BCDF), Toronto, Ontario, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Digit Symbol Substitution Test (DSST)|CogState Online Cognitive Battery|Trails Making Test (TMT)-A/B|Rey's auditory verbal learning test (RAVLT)|Perceived Deficits Questionnaire, 20-item (PDQ-20)|Fatigue Severity Scale (FSS)|Snaith Hamilton Pleasure Rating Scale (SHAPS)|Patient Health Questionnaire, 9-item (PHQ-9)|Generalized Anxiety Scale, 7-item (GAD-7)|World Health Organization Wellbeing Scale, 5-item (WHO-5)|EuroQol, 5-dimension, 5-level (EQ-5D-5L)|Sheehan Disability Scale (SDS)|Post-Covid Functional Scale (PCFS)
Export (.csv)